Kristine Yaffe1, Eric Vittinghoff, Mark J Pletcher, Tina D Hoang, Lenore J Launer, Rachel Whitmer, Laura H Coker, Stephen Sidney. 1. Departments of Psychiatry (K.Y.), Neurology (K.Y.), and Epidemiology and Biostatistics (K.Y., E.V., M.J.P.) and Division of General Internal Medicine, Department of Medicine (M.J.P.), University of California, San Francisco; San Francisco VA Medical Center, San Francisco, CA (K.Y.); Northern California Institute for Research and Education, San Francisco (T.D.H.); Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, MD (L.J.L.); Division of Research, Kaiser Permanente of Northern California, Oakland (R.W., S.S.); and Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC (L.H.C.).
Abstract
BACKGROUND: Studies have linked midlife and late-life cardiovascular risk factors (CVRFs) to cognitive function, yet little is known about CVRF exposure in early adulthood and subsequent cognitive function. In addition, most studies rely on single assessments of CVRFs, which may not accurately reflect long-term exposure. We sought to determine the association between cumulative exposure to CVRFs from early to middle adulthood and cognitive function at midlife. METHODS AND RESULTS: In a prospective study of 3381 adults (age, 18-30 years at baseline) with 25 years of follow-up, we assessed cognitive function at year 25 (2010-2011) with the Digit Symbol Substitution Test, Stroop Test, and Rey Auditory Verbal Learning Test analyzed with standardized z scores. The primary predictor was 25-year cumulative exposure estimated by areas under the curve for resting systolic and diastolic blood pressures, fasting blood glucose, and total cholesterol. Higher cumulative systolic and diastolic blood pressures and fasting blood glucose were consistently associated with worse cognition on all 3 tests. These associations were significant primarily for exposures above recommended guidelines; cognitive test z scores were between 0.06 and 0.30 points less, on average, for each 1-SD increase in risk factor area under the curve after adjustment for age, race, sex, and education (P<0.05 for all). Fewer significant associations were observed for cholesterol. CONCLUSIONS: Cumulative exposure to CVRFs from early to middle adulthood, especially above recommended guidelines, was associated with worse cognition in midlife. The meaning of this association and whether it warrants more aggressive treatment of CVRFs earlier in life require further investigation.
BACKGROUND: Studies have linked midlife and late-life cardiovascular risk factors (CVRFs) to cognitive function, yet little is known about CVRF exposure in early adulthood and subsequent cognitive function. In addition, most studies rely on single assessments of CVRFs, which may not accurately reflect long-term exposure. We sought to determine the association between cumulative exposure to CVRFs from early to middle adulthood and cognitive function at midlife. METHODS AND RESULTS: In a prospective study of 3381 adults (age, 18-30 years at baseline) with 25 years of follow-up, we assessed cognitive function at year 25 (2010-2011) with the Digit Symbol Substitution Test, Stroop Test, and Rey Auditory Verbal Learning Test analyzed with standardized z scores. The primary predictor was 25-year cumulative exposure estimated by areas under the curve for resting systolic and diastolic blood pressures, fasting blood glucose, and total cholesterol. Higher cumulative systolic and diastolic blood pressures and fasting blood glucose were consistently associated with worse cognition on all 3 tests. These associations were significant primarily for exposures above recommended guidelines; cognitive test z scores were between 0.06 and 0.30 points less, on average, for each 1-SD increase in risk factor area under the curve after adjustment for age, race, sex, and education (P<0.05 for all). Fewer significant associations were observed for cholesterol. CONCLUSIONS: Cumulative exposure to CVRFs from early to middle adulthood, especially above recommended guidelines, was associated with worse cognition in midlife. The meaning of this association and whether it warrants more aggressive treatment of CVRFs earlier in life require further investigation.
Authors: Kristine Yaffe; Alka Kanaya; Karla Lindquist; Eleanor M Simonsick; Tamara Harris; Ronald I Shorr; Frances A Tylavsky; Anne B Newman Journal: JAMA Date: 2004-11-10 Impact factor: 56.272
Authors: D S Knopman; A D Penman; D J Catellier; L H Coker; D K Shibata; A R Sharrett; T H Mosley Journal: Neurology Date: 2011-05-04 Impact factor: 9.910
Authors: A Solomon; I Kåreholt; T Ngandu; B Winblad; A Nissinen; J Tuomilehto; H Soininen; M Kivipelto Journal: Neurology Date: 2007-03-06 Impact factor: 9.910
Authors: Anouk G W van Norden; Ewoud J van Dijk; Karlijn F de Laat; Philip Scheltens; Marcel G M Olderikkert; F E de Leeuw Journal: Biochim Biophys Acta Date: 2011-07-14
Authors: Jared P Reis; Catherine M Loria; Lenore J Launer; Stephen Sidney; Kiang Liu; David R Jacobs; Na Zhu; Donald M Lloyd-Jones; Ka He; Kristine Yaffe Journal: Ann Neurol Date: 2013-02-26 Impact factor: 10.422
Authors: Lucy S Witt; Jason Rotter; Sally C Stearns; Rebecca F Gottesman; Anna M Kucharska-Newton; A Richey Sharrett; Lisa M Wruck; Jan Bressler; Carla A Sueta; Patricia P Chang Journal: J Gen Intern Med Date: 2018-07-20 Impact factor: 5.128
Authors: Marc B Lande; Donald L Batisky; Juan C Kupferman; Joshua Samuels; Stephen R Hooper; Bonita Falkner; Shari R Waldstein; Peter G Szilagyi; Hongyue Wang; Jennifer Staskiewicz; Heather R Adams Journal: J Pediatr Date: 2018-02-03 Impact factor: 4.406
Authors: Marc B Lande; Donald L Batisky; Juan C Kupferman; Joshua Samuels; Stephen R Hooper; Bonita Falkner; Shari R Waldstein; Peter G Szilagyi; Hongyue Wang; Jennifer Staskiewicz; Heather R Adams Journal: J Pediatr Date: 2016-09-29 Impact factor: 4.406